Phentermine for Obesity Management
Phentermine is indicated as a short-term adjunct (FDA-approved for "a few weeks," though commonly used longer in practice) for obesity management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities, dosed at 15-37.5 mg once daily in the morning, but should be reserved for younger patients without cardiovascular disease or uncontrolled hypertension due to its sympathomimetic effects. 1
Indications
Phentermine is FDA-approved for exogenous obesity management as part of a comprehensive regimen including:
- BMI ≥30 kg/m², OR
- BMI ≥27 kg/m² with weight-related comorbidities (controlled hypertension, diabetes, hyperlipidemia) 1
The medication works as an adrenergic agonist, activating the sympathetic nervous system to decrease food intake and increase resting energy expenditure 2.
Dosing Regimen
Standard dosing:
- 15-37.5 mg orally once daily in the morning (approximately 2 hours after breakfast) 2, 1
- Avoid late evening administration due to insomnia risk 1
- Can be taken with or without food 1
Low-dose option (Lomaira):
- 8 mg tablets up to 3 times daily (FDA-approved September 2016) 2
Renal impairment adjustments:
- Severe renal impairment (eGFR 15-29 mL/min/1.73 m²): Maximum 15 mg daily 1
- eGFR <15 mL/min/1.73 m² or dialysis: Avoid use 1
Expected Efficacy
From the 2023 JAMA obesity management guideline, phentermine-topiramate ER (which includes phentermine) achieves 9.2% weight loss versus 1.7% with placebo 3. Monotherapy data shows phentermine 15 mg daily produces 6.0 kg weight loss at 28 weeks, with 46% achieving ≥5% weight loss and 20.8% achieving ≥10% weight loss 2.
Absolute Contraindications
Cardiovascular:
- History of cardiovascular disease (coronary artery disease, stroke, arrhythmias, congestive heart failure)
- Uncontrolled hypertension 1
Psychiatric/Neurologic:
- Agitated states
- History of drug abuse
- Glaucoma 1
Metabolic:
- Hyperthyroidism 1
Drug interactions:
- Within 14 days of MAOI use (risk of hypertensive crisis) 1
- Concurrent use with other sympathomimetic amines 2
Reproductive:
- Pregnancy (Category X)
- Nursing mothers 1
Other:
- Known hypersensitivity to sympathomimetic amines 1
Patient Selection Considerations
Ideal candidates:
- Younger patients needing appetite suppression
- No active or unstable coronary disease
- Controlled or no hypertension
- No anxiety or insomnia (these conditions may be exacerbated) 2
Use caution in:
- Even mild hypertension (monitor for blood pressure increases) 1
- Patients on insulin or oral hypoglycemics (dose reduction may be required) 1
Monitoring Requirements
Cardiovascular monitoring:
- Blood pressure and heart rate (phentermine causes mild increases) 3, 2
- Consider baseline ECG in patients with cardiovascular risk factors, though this remains debated among specialists 4
Metabolic monitoring:
- Glucose levels if diabetic (insulin/oral hypoglycemic requirements may decrease) 1
- Hydration status 3
Efficacy monitoring:
- Weight loss assessment at regular intervals
- If tolerance develops (usually within a few weeks), discontinue rather than increase dose 1
Safety monitoring:
- New symptoms of dyspnea, angina, syncope, or lower extremity edema (rare primary pulmonary hypertension risk) 1
- Adverse effects: dry mouth, insomnia, dizziness, irritability 2, 1
Critical Warnings
Do not combine with other weight loss medications (including over-the-counter, herbal products, or serotonergic agents like SSRIs) - safety and efficacy not established 1.
Avoid alcohol - potential for adverse drug reactions 1.
Abuse potential: Schedule IV controlled substance; prescribe minimum feasible amounts to minimize overdosage risk 1.
Impaired activities: May impair ability to operate machinery or drive 1.
Duration of Therapy Controversy
While FDA-approved for "short-term" use (a few weeks) due to lack of long-term safety trials at the time of 1959 approval, many practitioners prescribe phentermine for longer durations in clinical practice 2. The 2023 JAMA guideline notes this discrepancy between FDA labeling and real-world use 3. An ongoing 24-month randomized trial (LEAP trial) is evaluating long-term efficacy and cardiovascular safety 5.
Common Pitfalls to Avoid
- Do not exceed recommended doses when tolerance develops - discontinue instead 1
- Screen for cardiovascular disease and uncontrolled hypertension before prescribing 2, 1
- Counsel women of reproductive potential about pregnancy risk (Category X) 2
- Check for MAOI use within past 14 days 1
- Avoid in patients with anxiety/insomnia who may experience worsening symptoms 2
Comparative Context
The 2023 JAMA guideline ranks anti-obesity medications by efficacy: tirzepatide (20.9% weight loss) > semaglutide (14.9%) > phentermine-topiramate ER (9.2%) 3. Phentermine monotherapy is less effective than newer GLP-1 agonists but remains the most commonly prescribed anti-obesity medication due to its low cost and long availability 2, 6.